AVITA Medical has signed a distribution agreement with PolyMedics Innovations to market its products in Europe.
As per the agreement, PolyMedics will serve as the exclusive distributor for Recell in Germany, Austria, and Switzerland, with an option for future expansion into other European markets.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Recell is an autologous cell harvesting device for treating thermal burn wounds, full-thickness skin defects, and for re-pigmentation of stable depigmented vitiligo lesions. It has received CE-mark approval in Europe, and approvals in the US, Australia, and Japan.
The US-based company also reported revenue of $13.5m in Q3 2023 and a net loss of $8.7m, as per AVITA’s Q3 financials. AVITA also expects US approval for its next-generation automated Recell device, RecellGo, in May 2024.
In October, AVITA secured a debt financing facility for up to $90m to support the development and commercialisation of its products.
Other devices in development for skin grafting include 3D-printed skin grafts using bio-inks. In May, Tissium raised €50m ($53.8m) in Series D financing to develop a 3D-printed implantable device and on-demand activated adhesive for sutureless nerve repair. Medical and dental 3D printing revenue has been steadily increasing since 2018 and is set to continue until at least 2026, as per GlobalData analysis.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn April, Kerecis launched a skin graft solution which combines a fish-skin graft and a silicone contact layer, MariGen Shield, to treat chronic and complex wounds. The main risk with these grafts is graft rejection, which can be avoided by using autologous tissue.
